Exec Chat: John Frels, VP Of Research And Development, Abbott Diagnostics
Executive Summary
Medtech Insight caught up with Abbott's John Frels to find out more on his approach to leading innovation and growth at the company.
You may also be interested in...
Abbott’s Blood Test For Traumatic Brain Injury Succeeds In Landmark Trial
A landmark trial of Abbott Laboratories' point-of-care blood test for traumatic brain injuries shows the test could identify patients who should undergo magnetic resonance imaging (MRI), even after a computed tomography (CT) scan did not show a brain injury.
Abbott Delivers Strong Q2 Sales, Led By Spike In FreeStyle Libre Sales
Abbott delivered solid sales growth in the second quarter of 2019, topping analyst expectations. The company reported worldwide sales of $8bn, up 2.7% with Medical Devices highlighted as a standout division, delivering 10.5% organic growth.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.